Portal de Periódicos da CAPES

Tumor Necrosis Factor Enhances the in Vitro and in Vivo Efficacy of Chemotherapeutic Drugs Targeted at DNA Topoisomerase II in the Treatment of Murine Bladder Cancer

1987; Lippincott Williams & Wilkins; Volume: 138; Issue: 2 Linguagem: Inglês

10.1016/s0022-5347(17)43178-8

1527-3792

Richard B. Alexander, John T. Isaacs, Donald S. Coffey,

Neuroendocrine Tumor Research Advances

No AccessJournal of Urology1 Aug 1987Tumor Necrosis Factor Enhances the in Vitro and in Vivo Efficacy of Chemotherapeutic Drugs Targeted at DNA Topoisomerase II in the Treatment of Murine Bladder Cancer Richard B. Alexander, John T. Isaacs, and Donald S. Coffey Richard B. AlexanderRichard B. Alexander , John T. IsaacsJohn T. Isaacs , and Donald S. CoffeyDonald S. Coffey View All Author Informationhttps://doi.org/10.1016/S0022-5347(17)43178-8AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Recombinant human tumor necrosis factor (rTNF) is a macrophage secretory protein with antitumor activity. The murine bladder tumor cell line MBT-2 was used to evaluate the in vitro and in vivo antitumor effects of rTNF in combination with chemotherapeutic drugs targeted at DNA topoisomerase II. These drugs, such as adriamycin and etoposide (VP 16), are in widespread use in the treatment of human cancer. The rTNF significantly enhanced the cytotoxic efficacy of the topoisomerase-targeted drugs actinomycin D, adriamycin, etoposide (VP 16) and teniposide (VM 26) against MBT-2 cells in vitro. The rTNF alone had no effect upon the cells in the same assay. When examined in vivo using MBT-2 tumor-bearing C3H/HeJ mice, these same antitumor relationships were seen. The addition of rTNF to actinomycin D or VP 16 resulted in a significant reduction in tumor volume at 20 days compared to untreated animals. Actinomycin D, VP 16 or rTNF treatment alone had no significant effect on 20 day tumor volume. The data provide a reasonable basis for the addition of rTNF to experimental protocols for the treatment of human bladder cancer using topoisomerase-targeted drugs such as adriamycin both intravesically and systemically. These observations may also be relevant to other human cancers currently treated with these drugs. (J. Urol., 138: 427-429, 1987) © 1987 by The American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited ByHofmockel G, Bassukas I, Heimbach D, Wirth M and Maurer-Schultze B (2018) Treatment of a Human Renal Cell Carcinoma in Nude Mice with Recombinant Human Tumor Necrosis Factor Alpha and EtoposideJournal of Urology, VOL. 150, NO. 6, (1974-1979), Online publication date: 1-Dec-1993.Liu S, Ewing M, Anglard P, Trahan E, La Rocca R, Myers C and Linehan W (2018) The Effect of Suramin, Tumor Necrosis Factor and Interferon γ on Human Prostate CarcinomaJournal of Urology, VOL. 145, NO. 2, (389-392), Online publication date: 1-Feb-1991.Steinberg G, Brendler C, Squire R and Isaacs J (2018) Experimental Intravesical Therapy for Superficial Transitional Cell Carcinoma in a Rat Bladder Tumor ModelJournal of Urology, VOL. 145, NO. 3, (647-653), Online publication date: 1-Mar-1991.Bahnson R and Ratliff T (2018) In Vitro and in Vivo Anti-Tumor Activity of Recombinant Mouse Tumor Necrosis Factor (TNF) in a Mouse Bladder Tumor (MBT-2)Journal of Urology, VOL. 144, NO. 1, (172-175), Online publication date: 1-Jul-1990.Amano T, Kumini K, Nakashima K, Uchibayashi T and Hisazumi H (2018) A Combined Therapy of Hyperthermia and Tumor Necrosis Factor for Nude Mice Bearing KK-47 Bladder CancerJournal of Urology, VOL. 144, NO. 2 Part 1, (370-374), Online publication date: 1-Aug-1990.Burgers J, Marshall F and Isaacs J (2018) Enhanced Anti-Tumor Effects of Recombinant Human Tumor Necrosis Factor Plus VP-16 On Metastatic Renal Cell Carcinoma in a Xenograft ModelJournal of Urology, VOL. 142, NO. 1, (160-164), Online publication date: 1-Jul-1989.Iizumi T, Yazaki T, Waku M and Soma G (2018) Immunochemotherapy for Murine Bladder Tumor with a New Human Recombinant Tumor Necrosis Factor (rTNF-S), VP-16 and HyperthermiaJournal of Urology, VOL. 142, NO. 2 Part 1, (386-389), Online publication date: 1-Aug-1989. Volume 138Issue 2August 1987Page: 427-429 Advertisement Copyright & Permissions© 1987 by The American Urological Association Education and Research, Inc.MetricsAuthor Information Richard B. Alexander More articles by this author John T. Isaacs More articles by this author Donald S. Coffey More articles by this author Expand All Advertisement Loading ...